<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02211859</url>
  </required_header>
  <id_info>
    <org_study_id>1216.2</org_study_id>
    <nct_id>NCT02211859</nct_id>
  </id_info>
  <brief_title>Dose Escalation Study of BI 2536 BS in Patients With Advanced Solid Tumours With Repeated Administration in Patients With Clinical Benefit</brief_title>
  <official_title>An Open Phase I Repeated Dose Escalation Study of BI 2536 BS Administered Intravenously in Patients With Advanced Solid Tumours With Repeated Administration in Patients With Clinical Benefit</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      Primary: Maximum tolerated dose (MTD) Secondary: Determination of the pharmacokinetic profile
      of BI 2536. Assessment of safety and efficacy.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2004</start_date>
  <primary_completion_date type="Actual">December 2007</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determination of the maximum tolerated dose (MTD) by occurrence of dose limiting toxicities (DLT)</measure>
    <time_frame>up to 3 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of patients with drug-related adverse events</measure>
    <time_frame>up to 24 days after last drug administration</time_frame>
    <description>according to common terminology criteria for adverse events (CTCAE) 3.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with abnormal laboratory findings</measure>
    <time_frame>up to 24 days after last drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Eastern Cooperative Oncology Group (ECOG) performance score</measure>
    <time_frame>baseline, up to 24 days after last drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with clinically significant changes in vital signs</measure>
    <time_frame>up to 24 days after last drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with objective tumor response</measure>
    <time_frame>up to 24 days after last drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax (maximum concentration of the analyte in plasma)</measure>
    <time_frame>up to 264 hours after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>tmax (time from dosing to maximum concentration)</measure>
    <time_frame>up to 264 hours after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-∞ (area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity)</measure>
    <time_frame>up to 264 hours after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>%AUC0-tz (the percentage of the AUC0-∞ that is obtained by extrapolation)</measure>
    <time_frame>up to 264 hours after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>λz (terminal rate constant in plasma)</measure>
    <time_frame>up to 264 hours after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2 (terminal half-life of the analyte in plasma)</measure>
    <time_frame>up to 264 hours after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MRT (mean residence time of the analyte in the body after intravenous administration)</measure>
    <time_frame>up to 264 hours after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL (total clearance of the analyte in the plasma after intravascular administration)</measure>
    <time_frame>up to 264 hours after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vz (apparent volume of distribution during the terminal phase λz following an intravascular dose)</measure>
    <time_frame>up to 264 hours after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vss (apparent volume of distribution at steady state following intravascular administration)</measure>
    <time_frame>up to 264 hours after drug administration</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">70</enrollment>
  <condition>Neoplasms</condition>
  <arm_group>
    <arm_group_label>BI 2536</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single escalating dose, followed by repeated administration in patients with clinical benefit</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 2536</intervention_name>
    <arm_group_label>BI 2536</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Patients with confirmed diagnosis of advanced, non resectable and/or metastatic solid
             tumours, who have failed conventional treatment, or for whom no therapy of proven
             efficacy exists, or who are not amenable to established forms of treatment

          -  Evaluable tumour deposits

          -  Age 18 years or older

          -  Life expectancy of at least six months

          -  Written informed consent consistent with international conference of harmonization
             (ICH) - good clinical practice (GCP) and local legislation

          -  Eastern Cooperative Oncology Group (ECOG) performance score ≤ 2

          -  Full recovery from all therapy-related toxicities from previous chemo-, hormone-,
             immuno-, or radiotherapies

        Exclusion Criteria:

          -  Serious illness or concomitant non-oncological disease considered by the investigator
             to be incompatible with the protocol

          -  Pregnancy or breastfeeding

          -  Active infectious disease

          -  Known brain metastases

          -  Second malignancy requiring therapy

          -  Absolute neutrophil count less than 1500/mm3

          -  Platelet count less than 100 000/mm3

          -  Bilirubin greater than 1.5 mg/dl (&gt; 26 μmol/L)

          -  Aspartate amino transferase (AST) and/or alanine amino transferase (ALT) greater than
             2.5 times the upper limit of normal (if related to liver metastases greater than five
             times the upper limit of normal)

          -  Serum creatinine greater than 1.5 mg/dl (&gt; 132 μmol/L)

          -  Women and men who are sexually active and unwilling to use a medically acceptable
             method of contraception

          -  Treatment with other investigational drugs or participation in another clinical trial
             within the past four weeks before start of therapy or concomitantly with this trial
             (except for present trial drug)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <link>
    <url>http://trials.boehringer-ingelheim.com</url>
  </link>
  <verification_date>August 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 7, 2014</study_first_submitted>
  <study_first_submitted_qc>August 7, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 8, 2014</study_first_posted>
  <last_update_submitted>August 7, 2014</last_update_submitted>
  <last_update_submitted_qc>August 7, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 8, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

